UCB to File for Two More Cimzia Arthritis Indications This Year, Tables Another RA Candidate

UCB plans to submit marketing applications for Cimzia in psoriatic arthritis and axial spondyloarthritis (AxSpA), including ankylosing spondylitis, to the FDA and EU by the end of the year.  The filings follow positive Phase III results for the drug in both indications reported earlier this year.
Drug Industry Daily